Palisade Bio jumps following Oppenheimer outperform initiation
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. The investment bank has an $8 price target (321% upside based on July 22 close). Analyst Lelend Gershell sees strong potential in PALI-2108, which
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪The investment bank has an $8 price target (321% upside based on July 22 close).
- ▪Analyst Lelend Gershell sees strong potential in PALI-2108, which
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/news/4617467-palisade-bio-jumps-following-oppenheimer-outperform-initiation"},"author":{"@type":"Person","name":"Jonathan Block","url":"https://seekingalpha.com/user/53161691"},"publisher":{"@context":"https://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
